Five-year outcomes with alemtuzumab induction after lung transplantation
Open Access
- 31 July 2011
- journal article
- research article
- Published by Elsevier BV in The Journal of Heart and Lung Transplantation
- Vol. 30 (7), 743-754
- https://doi.org/10.1016/j.healun.2011.01.714
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult lung and heart-lung transplant report—2010The Journal of Heart and Lung Transplantation, 2010
- Current Trends in Immunosuppression for Lung TransplantationSeminars in Respiratory and Critical Care Medicine, 2010
- Alemtuzumab Induction Prior to Cardiac Transplantation with Lower Intensity Maintenance Immunosuppression: One-Year OutcomesAmerican Journal of Transplantation, 2010
- Lung allograft rejection: diagnosis and managementCurrent Opinion in Organ Transplantation, 2009
- Immunobiology of Chronic Lung Allograft Dysfunction: New Insights from the Bench and BeyondAmerican Journal of Transplantation, 2009
- Campath Induction for Kidney Transplantation: Report of 297 CasesTransplantation, 2008
- Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With AlemtuzumabAmerican Journal of Transplantation, 2007
- Clinical Research, Innovative Practice and IRB Review: Identifying and Respecting BoundariesAmerican Journal of Transplantation, 2007
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- Minimal Acute Rejection after Lung Transplantation: A Risk for Bronchiolitis Obliterans SyndromeAmerican Journal of Transplantation, 2005